Therapeutic flag Cosmetic cross-reference

Sucrose

CAS 57-50-1

Sucrose (CAS 57-50-1) is a Phase 3 pharmaceutical compound with 5 bioactivity targets and 366 adverse event associations.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
5
SOURCE DrugCentral
Adverse signals
366
SOURCE IUPHAR/BPS
PubMed IDs
0
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
Sucrose
CAS Number
57-50-1
UNII
C151H8M554
InChIKey
CZMRCDWAGMRECN-UGDNZRGBSA-N
ChEMBL ID
CHEMBL253582
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
natural producttherapeutic flag
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 3
Late-stage clinical development phase from the compound identifier source.
ChEMBL CHEMBL253582 | Small molecule
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →
SOURCE EMBL-EBI ChEMBL 5 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

TargetActivity ValueAssaysOrganism
- AC50 30000 nM 101 -
- MIC 41.42857142857143 ug 7 -
- IC50 26658.77 nM 5 -
- Ki 20000 nM 2 -
- Potency 40.5 nM 1 -
SOURCE DrugCentral 30 associations

Adverse Event Associations

DrugCentral / FAERS disproportionality signal rows matched to this compound.

Reaction PTDrug AE LLRMedDRA
Appendicolith 54 219.789 10074458
Appendicitis 54 166.112 10003011
Cardiogenic shock 54 132.665 10007625
Blood phosphorus increased 38 131.984 10050196
Ventricular fibrillation 50 130.946 10047290
Abdominal distension 69 108.784 10000060
Stress 58 103.278 10042209
Ascites 55 98.968 10003445
Blood uric acid increased 32 94.986 10005861
Myasthenia gravis 29 90.979 10028417
Multiple organ dysfunction syndrome 56 81.281 10077361
Dry mouth 49 73.723 10013781
Hyponatraemia 58 66.871 10021036
Constipation 70 55.31 10010774
Abdominal pain 78 53.981 10000081
Drug therapy 12 53.356 10063370
General physical health deterioration 64 51.33 10049438
Analgesic therapy 11 49.955 10053469
Sleep disorder therapy 11 49.729 10040990
Sepsis 61 46.158 10040047
Neuralgia 24 41.712 10029223
Hyperphosphataemia 14 41.112 10020711
Somnolence 49 32.832 10041349
Blood cholesterol increased 31 32.175 10005425
Incorrect route of product administration 21 31.849 10081202
Nausea 109 29.462 10028813
Vomiting 82 27.045 10047700
Bacterial infection 18 27.001 10060945
Hypophosphataemia 14 24.879 10021058
Thrombosis 25 22.098 10043607

Association rows are source-linked signal records, not incidence rates or clinical causality claims.

SOURCE NLM RxNorm 4 name rows

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

NameRxCUI TypeSource
SUCROSE 10159 SU MTHSPL
Sucrose 10159 SU MTHSPL
sucrose 10159 SU MTHSPL
sucrose 10159 IN RXNORM
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Sucrose used for in pharmaceutical contexts?

Sucrose (CAS 57-50-1) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Sucrose?

Sucrose has 366 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Appendicolith, Appendicitis, Cardiogenic shock, Blood phosphorus increased, Ventricular fibrillation. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Sucrose also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Sucrose with EU status "permitted".

What clinical phase is Sucrose in?

Sucrose is rendered with ChEMBL max phase 3.